Business Wire

Top UK university hospital unveils data that support the use of rapid infusion for Truxima® (CT-P10, biosimilar rituximab) in patients with advanced-stage follicular lymphoma

Jaa

New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were presented this weekend at the 59th American Society of Hematology (ASH) Annual Meeting. The results showed that rapid infusion of CT-P10 was well-tolerated across all patient groups and patients could be safely switched from reference rituximab to CT-P10 without reverting to slower infusion rates1.

The independent study examined the infusion-related reactions (IRRs) in three different patient groups: rituximab naive, those switching directly from reference rituximab to CT-P10, and those that received their last dose of reference rituximab at least 6 months prior to the study.1

The administration of rituximab is associated with IRRs which occur most frequently during the first infusion. To reduce the risk of IRRs, it is the manufacturers’ recommendation that the first dose is increased every 30 minutes in 50mg/hour increments resulting in a typical rituximab infusion taking 4-6 hours. It is common practice however to administer rituximab as a rapid infusion if the first infusion is well-tolerated which reduces infusion time to just over an hour and 30 minutes.1

Mr. Simon Cheesman from the University College London Hospitals NHS Foundation Trust and one of the authors of the study said, “We felt that it was important to investigate the safety of using rapid infusion for CT-P10 as this method of infusion for reference rituximab is of significant benefit to patients, taking hours off their treatment time. The findings from the study should help to increase physician confidence and facilitate the introduction of CT-P10 at centres prescribing rituximab across the UK and beyond”.

Man Hoon Kim, President and CEO of Celltrion Healthcare, welcomed the findings from UCLH’s study commenting: “The study by UCLH is of significant importance as it demonstrates that CT-P10 can be safely administered as a rapid infusion without physicians having to revert to the slower infusion rate. This not only saves hospitals’ valuable time and resources but also greatly improves the patient experience”.

The ASH meeting also saw Celltrion Healthcare present pharmacokinetic (PK) data for CT-P10, which compared the PK properties of CT-P10 and reference rituximab according to several relevant clinical factors in patients with advanced-stage follicular lymphoma. The results showed that the PK of CT-P10 is in accordance with historical data about reference rituximab and further supports the PK similarity between CT-P10 and reference rituximab across all patient sub-groups2.

--- Ends---

Notes to editors:

About CT-P10 (biosimilar rituximab)

CT-P10 is a mAb that targets CD20, a transmembrane protein found on the surface of most B cells. By binding specifically to CD20, CT-P10 depletes B cells by three main mechanisms: Induction of apoptosis, stimulation of CDC (complement-dependent cytotoxicity) and stimulation of ADCC (antibody-dependent cell-mediated cytotoxicity).

CT-P10 is approved in the EU for the treatment of patients with Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. Further details of the approved indications and safety information for CT-P10 are available in the summary of product characteristics (SmPC).3

About Advanced FL

Follicular lymphomas are the second most frequent subtype of nodal lymphoid malignancies in Western Europe4 and are a subtype of NHL.5 It is a slow-growing lymphoma that develops from B lymphocytes (B cells). It is characterized by painless swelling of the lymph nodes, fever for no apparent reason, drenching night sweats, fatigue, infections and bleeding. Most cases are advanced at the time of diagnosis but since the advent of rituximab, overall survival has increased to in excess of 20 years. It is called ‘follicular’ lymphoma because the abnormal lymphocytes often collect in lymph nodes in clumps that are known as ‘follicles’. Follicular lymphoma is more common in people aged over 65, but it can occur in people of any age.

About CT-P10 Advanced FL 24 week study 6

This Phase III, randomised, parallel-group, active-controlled, double-blind study aims to demonstrate equivalence of pharmacokinetics and non-inferiority of efficacy for CT-P10 in comparison with reference rituximab, each administered in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with advanced FL.

A total of 121 patients were included in the results presented at the ASH meeting.2 Fifty-nine patients in the CT-P10 group and 62 patients in the reference rituximab group received CT-P10 or reference rituximab plus CVP every 3 weeks over 8 cycles. No statistically significant differences were found between the two groups in PK properties in all subgroup analyses.

Data previously published in The Lancet Haematology in 2017 showed that CT-P10 was non-inferior to reference rituximab in advanced FL in terms of efficacy.7

About Celltrion Healthcare

Celltrion Healthcare conducts the worldwide marketing, sales and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network that spans more than 120 different countries. Celltrion Healthcare’s products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US Food and Drug Administration (FDA) cGMP guidelines and the EU GMP guidelines. For more information please visit: http://www.celltrionhealthcare.com/

References

1 Shah et al. Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® - the University College London Hospitals (UCLH) Experience. 59th Annual Meeting of the American Society of Hematology (ASH). 2017. 3387.

2 Won Seog Kim et al. Clinical Factors Impact on Pharmacokinetics of CT-P10 and Reference Rituximab in Patients with Advanced-Stage Follicular Lymphoma. 59th Annual Meeting of the American Society of Hematology (ASH). 2017. 1504.

3 Truxima concentrate for solution for infusion summary of product characteristics [last accessed December 2017]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.

4 Dreyling, M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83-v90 doi:10.1093/annonc/mdw400.

5 Kohrt HEK & Ugarte A. Follicular Lymphoma: a Guide for Patients. European Society for Medical Oncology. 2014. Available at: https://www.esmo.org/content/download/52236/963497/file/EN-Follicular-Lymphoma-Guide-for-Patients.pdf [accessed December 2017].

6 Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma [last accessed December 2017]. Available at: https://clinicaltrials.gov/ct2/show/NCT02162771.

7 Won Seog Kim et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. The Lancet Haematology 4.8 (2017): e362-e373.

Contact information

Hanover for Celltrion Healthcare
Emma Gorton
egorton@hanovercomms.com
+44 (0)20-3817-6591
or
Georgia Featherston
gfeatherston@hanovercomms.com
+44 (0)20-3817-6718

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

GSMA Marks International Girls in ICT Day with Events around the World25.4.2018 11:00Tiedote

The GSMA will celebrate the annual ITU International Girls in ICT Day this week with a series of events across its global footprint aimed at encouraging and empowering young women to explore career opportunities in the science, technology, engineering and mathematics (STEM) areas and helping companies worldwide reap the benefits of greater female participation in the tech sector. The 2018 ITU International Girls in ICT Day will be held on Thursday 26 April and will be marked by events run by local GSMA offices in Atlanta, Barcelona, Brussels, Dubai, Hong Kong, London and Nairobi. “The GSMA is delighted to be supporting the ITU International Girls in ICT event for the fifth year running, inviting girls from around the world to learn about the rewarding careers possible within the mobile industry and the wider ICT sector,” said Mats Granryd, Director General, GSMA. “The future success of our industry rests on the ability to attract talented females and we hope to inspire a new generation

Kela: Contrary to Reports, the Basic Income Experiment in Finland Will Continue until the End of 201825.4.2018 10:31Tiedote

Many international media-outlets have published stories alleging that Finland is going to discontinue its basic income experiment. This information is incorrect. “The experiment is proceeding according to plan and will continue until the end of 2018”, says Professor Olli Kangas, the leader of the research team at Kela (Social Insurance Institution of Finland). There are currently no plans to continue or expand the experiment after 2018. The effects will be studied after the experiment has ended The employment effects across the whole experiment will be available by the end of 2019 or at the beginning of 2020. “The effects of the experiment will not be published while the experiment is in progress, because a public discussion of the results could influence the behaviour of the test and control groups. That would lead to skewed results”, Kangas says. The basic income experiment was launched in January 2017. During the experiment, the 2,000 participants are receiving a EUR 560 monthly bas

GSMA Announces Additional Keynote Speakers for Mobile World Congress Shanghai 201825.4.2018 10:00Tiedote

The GSMA today announced that executives from leading organisations across the mobile ecosystem will participate in the keynote programme at the 2018 GSMA Mobile World Congress Shanghai. The GSMA also announced the first speakers for the new Leaders Stage, as well as newly confirmed exhibitors, partners, sponsors and events. Mobile World Congress Shanghai will take place 27-29 June at the Shanghai New International Expo Centre (SNIEC). “With just over two months to go, we have a very exciting programme lined up for Mobile World Congress Shanghai 2018,” said Michael O’Hara, Chief Marketing Officer. “While showcasing the latest developments in mobile, this year’s event will offer attendees a wide range of experiences through the conference, the exhibition and specialised programmes such as Women4Tech, 4YFN and beyond.” New Keynote Speakers Confirmed The GSMA announced several additional keynote speakers for Mobile World Congress Shanghai, with executives from leading mobile operators, in

News Services Group Officially Announces the Rebranding of ME NewsWire to AETOSWire25.4.2018 10:00Tiedote

News Services Group (NSG) officially announces the rebranding of its news distribution arm ME NewsWire to AETOSWire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425005116/en/ Tony AbiHanna, President and CEO of NSG, AETOSWire and Esmaa News, explained the reason behind this timely move: “In 10 years, we have grown exponentially as a company. Middle East (ME) NewsWire as a name no longer encompasses the real essence and depth of our services. Hence, we handpicked a new brand name that we believe reflects who we are now and will continue to embody us in the future.” The name “AETOS” captures the heart and soul of the company’s services. It’s derived from Greek Mythology, AETOS DIOS, which translates to “The Eagle of Zeus.” AETOS is the Giant , Trusted, Loyal, Fast and Personal Messenger of Zeus, the very same characteristics that the company brings to its valued and esteemed clientele. Today, AETOSWire has the largest an

IAB Europe and IAB Tech Lab Release Cross-Industry Transparency & Consent Framework for Adoption25.4.2018 10:00Tiedote

IAB Europe and IAB Technology Laboratory today released the market-ready technical specifications for the Transparency & Consent Framework (“Framework”) following a 30-day public consultation in March and April 2018. The official release version of the standard reflects extensive feedback from publishers, agencies, and ad tech companies collected during the consultation period. As with all standards, it is expected that this standard will be iterated with new features and attributes in the future. The Framework allows users to have full authority over their data. The Framework is a cross-industry standard that supports online services and their partners in their efforts to provide transparency and choice mechanisms for their users. In accordance with the General Data Protection Regulation (GDPR), users can now be made aware of not only online services’ use of their users’ personal data, but also use of that data by third parties that assist online services in showing advertisements to

Digital Element Partners with Discovery Inc. to Enhance the Company’s Video Rights Accuracy with Location-Based Technology25.4.2018 10:00Tiedote

Digital Element, the global geolocation data and services provider, today announced that global media company, Discovery Inc., has adopted its NetAcuity hyperlocal IP geolocation technology, to ensure the right people see the right content and remain compliant with geographic rights across Europe. Discovery has a global reach of more than three billion viewers across more than 220 countries and territories and is home of leading TV offerings including Eurosport, Discovery Channel and Animal Planet, to name a few. The internationally-renowned brand reaches audiences across screens through digital-first programming from providers including Group Nine Media, Discovery VR, and Eurosport Player. European telecommunications companies often operate across numerous territories and distribute IP addresses to multiple regions, which can make the management of geographic TV rights complex. By adopting Digital Element's IP intelligence solution, NetAcuity, which enables the identification of the p

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme